Pfizer Inc. (PFE)
Ameriprise Financial Inc. Increases Holdings in Pfizer Inc. $PFE
Ameriprise Financial Inc. grew its stake in Pfizer Inc. (NYSE: PFE) by 48.2% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,373,140 shares of the biopharmaceutical company's stock after acquiring an additional 5,978,927 shares during the quarter. Ameriprise Financial Inc. owned
44 Wealth Management LLC Buys Shares of 24,551 Pfizer Inc. $PFE
44 Wealth Management LLC bought a new position in Pfizer Inc. (NYSE: PFE) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 24,551 shares of the biopharmaceutical company's stock, valued at approximately $626,000. A number of other institutional investors and
Game Creek Capital LP Trims Stake in Pfizer Inc. $PFE
Game Creek Capital LP cut its holdings in Pfizer Inc. (NYSE: PFE) by 23.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 127,500 shares of the biopharmaceutical company's stock after selling 40,125 shares during the period. Pfizer accounts for 1.1%
Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation
Pfizer Inc. (PFE) is undervalued at 8–9× forward earnings, offering a nearly 7% dividend yield and significant upside potential. Recent acquisitions, especially Seagen, position PFE for robust growth, with Seagen's revenue projected to exceed $10 billion by 2030. Cost-cutting initiatives and a strong core portfolio support dividend sustainability and margin improvement despite post-COVID revenue declines.
1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
Pfizer has been hurt in recent years after the COVID-19 pandemic and recent drug pricing pressure. The stock now trades at a dividend yield of 6.5%.
Pfizer (PFE) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Pfizer (PFE) closed the most recent trading day at $26.86, moving 1.61% from the previous trading session.
Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study
U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin disease met the main goal in a mid-stage study.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
China approves Pfizer GLP-1 drug for weight management
China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight management in overweight or obese adults, the US drugmaker said on WeChat on Friday, boosting competition in a market analysts expect to be worth billions in coming years.
Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund
A federal judge on Thursday awarded Pfizer $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider trading settlement with billionaire Steven A. Cohen's former hedge fund SAC Capital Management.
Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
PFE faces falling COVID sales, looming patent cliffs and IRA pressure. It is betting on cost cuts, new launches and pipeline rebuilds to revive growth.
